Sobi(TM) - First Patient Randomised in a Phase 3 Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Still's Disease

STOCKHOLM, Nov. 16, 2017 -- (Healthcare Sales & Marketing Network) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the first patient has been randomised in the phase 3 study anaSTILLs, to evaluate efficacy and safety of anakinra in the treatm... Biopharmaceuticals Swedish Orphan Biovitrum, Sobi , anakinra, Still's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news